Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Summary
  • The company usually posts poor financials for mid or long term investments.
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The company is in a robust financial situation considering its net cash and margin position.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • The company's enterprise value to sales, at 4.53 times its current sales, is high.
  • The company benefits from high valuations in earnings multiples.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
MERCK AND COMPANY7.88%174 223
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
AMGEN27.41%133 501
SANOFI9.90%124 704
BAYER19.94%114 930
BRISTOL-MYERS SQUIBB COMPAN..10.66%105 644
NOVO NORDISK A/S24.77%99 069
GLAXOSMITHKLINE-1.66%98 802
ABBOTT LABORATORIES45.20%97 853
ELI LILLY AND COMPANY16.56%96 039
CELGENE CORPORATION18.51%94 923
ASTRAZENECA16.62%85 977
ALLERGAN PLC-10.89%62 943
More Results
Financials ($)
Sales 2017 40 270 M
EBIT 2017 13 680 M
Net income 2017 5 793 M
Debt 2017 8 103 M
Yield 2017 2,95%
P/E ratio 2017 31,87
P/E ratio 2018 19,03
EV / Sales 2017 4,53x
EV / Sales 2018 4,45x
Capitalization 174 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart MERCK AND COMPANY
Duration : Period : Day
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Duration : Period : Week
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders